

QIBA Process Committee Call

Tuesday, February 4, 2020 at 3 pm CT

Call Summary

Attendees:

Kevin O'Donnell, MASC (Chair)

Michael Boss, PhD (Vice Chair)

Nancy Obuchowski, PhD

Nicholas Petrick, PhD

Daniel Sullivan, MD

Gudrun Zahlmann, PhD

RSNA Staff:

Fiona Miller

Julie Lisiecki

Wiki Updates

- Mr. O'Donnell to create a wiki page for the Metrology Committee
- Appropriate placement for this page was discussed
- RSNA Staff to post content (e.g. call summaries, roster) and any other content provided by Dr. Obuchowski
- Mr. O'Donnell suggested posting the [Metrology 2019 poster](#) or a segment from the poster

Proposed Topics for Further Discussion

- How to check attestation by clinical sites and third-party certification
- Model for the [Accumetra conformance certificate services](#)

[Public Comment Resolution](#)

- Only one public comment resolution document has been posted (CT Volumetry BC: Advanced Disease)
- Reminder needed for BC leaders and Profile editors to wiki post these documents once available
 - It is important to demonstrate to the broader community that their suggestions have been carefully considered and incorporated
- It was proposed that a consensus vote would not be allowed until the comment resolution document has been posted to the QIBA wiki
 - Building this step into the review process will ensure that resolution documents are posted
 - Mr. O'Donnell to provide some language for review
 - Once finalized, BC leaders to be informed of this new step

[Stakeholder Viewpoints](#)

- **CRO/Pharma:** Dr. Zahlmann to draft text for this wiki page, with input from InviCRO partners and pharma
- **QIBA for Statisticians** may be another area to develop
- **Physicists:** Mr. O'Donnell to follow up with Drs. Armato, Chenevert, and Kinahan for short descriptions of their experiences with the QIBA Process and its usefulness
- To appeal to a broader audience, it was suggested that personal vignettes be added, providing testimonials regarding how QIBA has been helpful

QIBA RIC Committee

- Though the QIBA-RIC Committee is no longer active, it was never officially labeled as *dormant* or *dissolved*; so, a formal vote is needed at the next QIBA Executive Committee meeting

Biomarker Adoption Steps and Supporting Materials

- Review continued of Mr. O'Donnell's [Google Document](#), which was developed to provide a common understanding of how QIBA materials are used and by whom
- Drs. Boss and Zahlmann have some details they would like to add to this document
- New biomarker proposals were discussed in terms of cost-benefit and risk
- Dr. Zahlmann discussed InviCRO as an example, noting that the real monetary benefit to them is considerable and that clinical trial and core lab engagement is critical
 - Also noted, were that details regarding accreditation bodies are missing and should be added
- Dr. Sullivan mentioned a discussion he had with Angela Colmone at RSNA about the need for QIBA to better emphasize the value of QIBA to its stakeholders
 - Dr. Sullivan noted this is the overarching theme of the 2020 QIBA Annual Meeting and that the intersection with the RSNA strategic plan is AI
 - Input from Quantitative Imaging (QI) is critical to obtain good data/output essential for AI development and testing
 - Dr. Zahlmann noted that the QIBA message needs to be made more explicit that quantitation is essential and is the foundation for AI
 - Dr. Boss added that good quantitative data is necessary for demonstrating reproducibility of results
 - An internal document is being drafted by Mr. O'Donnell addressing these topics; it will include how to organize testing conformance and the testing process
 - Dr. Zahlmann to send an email to Mr. O'Donnell summarizing her ideas
- Dr. Boss mentioned an ECOG-ACRIN FDG trial (EA1183) for METS, which is considering assessing the feasibility of the QIBA FDG-PET/CT Profile
- Feedback from trial leaders has included the following:
 - Checklists contain redundancies and are too long
 - Due to additional time needed, utilizing the Profile may hurt accrual and site qualification
- Dr. Boss asked for opinions on how the QIBA FDG-PET BC should respond to these comments and how to address the lack of Profile adoption
 - Dr. Kinahan has been championing the QIBA FDG-PET Profile and has taken the lead in responding to Dr. Mankoff
 - Process Committee members agreed that this is a conundrum and suggested additional marketing efforts and persuading sites via their connections to utilize QIBA Profiles

Action items:

- Conformance testing, record testing and communicating conformance to be discussed during the next call
- All are asked to review these sections in the Google document and be prepared to discuss them

Next Process Cmte Call: Tuesday, February 18, 2020 at 3 pm CT (1st & 3rd weeks of each month)